Trade body illustrates value of European pharma investment

27 June 2019

A new report from European pharma trade group EFPIA finds that around 2.5 million jobs in Europe are supported by the sector, with an average “Gross Value Added” per employee of 156,000 euros ($177,000), significantly higher than that of other key sectors.

EFPIA - The European Federation of Pharmaceutical Industries and Associations - commissioned PwC to complete the analysis, which assesses the economic and social footprint of the pharmaceutical industry in Europe.

With the USA pacing ahead on new drug approvals, and with increasing competition from China, the EFPIA is concerned that Europe may be falling behind in the global race for talent and investment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK